scholarly article | Q13442814 |
P50 | author | Mariano Barbacid | Q3329034 |
P2093 | author name string | Carmen Guerra | |
P2860 | cites work | Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas | Q24299520 |
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses | Q24606006 | ||
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
Notch signalling controls pancreatic cell differentiation | Q28504686 | ||
EGF receptor is required for KRAS-induced pancreatic tumorigenesis | Q28584901 | ||
Albumin-bound paclitaxel: a next-generation taxane | Q29027108 | ||
Recapitulation of elements of embryonic development in adult mouse pancreatic regeneration | Q46376132 | ||
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas | Q46708964 | ||
Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. | Q51056982 | ||
Expression of murine STF-1, a putative insulin gene transcription factor, in beta cells of pancreas, duodenal epithelium and pancreatic exocrine and endocrine progenitors during ontogeny. | Q51128200 | ||
Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. | Q51894736 | ||
Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. | Q53329413 | ||
The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. | Q53379869 | ||
Expression patterns of epiplakin1 in pancreas, pancreatic cancer and regenerating pancreas. | Q53475736 | ||
Pancreatic Cancer | Q54135367 | ||
Update on Familial Pancreatic Cancer | Q57953769 | ||
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer | Q60594558 | ||
Chronic Pancreatitis Is Essential for Induction of Pancreatic Ductal Adenocarcinoma by K-Ras Oncogenes in Adult Mice | Q61776577 | ||
Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice | Q63283423 | ||
Growth effects of regulatory peptides and intracellular signaling routes in human pancreatic cancer cell lines | Q64038852 | ||
Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy | Q73086227 | ||
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis | Q73614651 | ||
Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression | Q77464625 | ||
Pancreatic fibrosis associated with age and ductal papillary hyperplasia | Q80380530 | ||
The expression and clinical significance of pSTAT3, VEGF and VEGF-C in pancreatic adenocarcinoma | Q82498658 | ||
Surgery for chronic pancreatitis decreases the risk for pancreatic cancer: a multicenter retrospective analysis | Q84991668 | ||
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer | Q29547558 | ||
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Q29614348 | ||
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis | Q29614405 | ||
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers | Q29615475 | ||
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma | Q29616287 | ||
Pancreatic cancer | Q29616288 | ||
DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1 | Q29616726 | ||
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice | Q29617045 | ||
The patterns and dynamics of genomic instability in metastatic pancreatic cancer | Q29618121 | ||
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse | Q29620396 | ||
Pancreatic cancer | Q29622871 | ||
KRAS2 mutations in human pancreatic acinar-ductal metaplastic lesions are limited to those with PanIN: implications for the human pancreatic cancer cell of origin | Q33408107 | ||
Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas | Q33486497 | ||
Isolation and characterization of centroacinar/terminal ductal progenitor cells in adult mouse pancreas | Q33591500 | ||
Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice | Q33604913 | ||
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials | Q33767211 | ||
Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study | Q33834355 | ||
Mucinous cystic neoplasms of the pancreas | Q33865956 | ||
Genetic progression in the pancreatic ducts | Q33943167 | ||
Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma | Q34068002 | ||
Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection | Q34620078 | ||
Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras | Q34620985 | ||
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial | Q34632818 | ||
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma | Q34642090 | ||
p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions | Q34727942 | ||
Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice | Q34733426 | ||
Stat3 and MMP7 contribute to pancreatic ductal adenocarcinoma initiation and progression. | Q34786695 | ||
Oncogenic Ras/Src cooperativity in pancreatic neoplasia. | Q35015392 | ||
A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease | Q35076746 | ||
Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression | Q35127700 | ||
Hedgehog/Ras interactions regulate early stages of pancreatic cancer | Q35127709 | ||
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development | Q35178284 | ||
NF-kappaB in pancreatic cancer | Q35196538 | ||
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma | Q35369888 | ||
Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. | Q35529084 | ||
Risk of pancreatic adenocarcinoma in chronic pancreatitis | Q35595218 | ||
Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. | Q35619635 | ||
Germline Brca2 Heterozygosity Promotes KrasG12D -Driven Carcinogenesis in a Murine Model of Familial Pancreatic Cancer | Q39635066 | ||
Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha | Q39635625 | ||
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival | Q39761203 | ||
Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma | Q39885220 | ||
A paracrine requirement for hedgehog signalling in cancer | Q39946287 | ||
Notch signaling is required for exocrine regeneration after acute pancreatitis. | Q40017803 | ||
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice | Q40679145 | ||
Notch1 functions as a tumor suppressor in a model of K-ras-induced pancreatic ductal adenocarcinoma | Q40865845 | ||
Role of growth factors in pancreatic cancer. | Q41690572 | ||
Hedgehog signaling is required for effective regeneration of exocrine pancreas | Q41761890 | ||
Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma | Q41856856 | ||
Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer | Q42147260 | ||
Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence | Q42573716 | ||
Aspirin use and pancreatic cancer risk | Q43054442 | ||
Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes | Q43470250 | ||
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. | Q45345249 | ||
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways | Q35641254 | ||
The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia | Q35663506 | ||
Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia | Q35747777 | ||
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma | Q35825974 | ||
Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia | Q35928158 | ||
Identification and analysis of precursors to invasive pancreatic cancer. | Q35948700 | ||
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma | Q36036234 | ||
β-catenin is selectively required for the expansion and regeneration of mature pancreatic acinar cells in mice | Q36051065 | ||
Precursors to invasive pancreatic cancer | Q36054500 | ||
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. | Q36182645 | ||
Bmi1 is required for regeneration of the exocrine pancreas in mice | Q36359854 | ||
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer | Q36550798 | ||
Hepatocyte nuclear factor 3beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene | Q36573166 | ||
Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. | Q36617328 | ||
Genetically engineered mouse models of pancreatic cancer | Q36675786 | ||
EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma | Q36696146 | ||
Cancer-associated stromal fibroblasts promote pancreatic tumor progression | Q36844475 | ||
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer | Q36901035 | ||
Inhibition of the hedgehog pathway targets the tumor-associated stroma in pancreatic cancer | Q36936500 | ||
Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia | Q36980230 | ||
Spontaneous induction of murine pancreatic intraepithelial neoplasia (mPanIN) by acinar cell targeting of oncogenic Kras in adult mice | Q36999854 | ||
Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia | Q37040899 | ||
GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation | Q37075682 | ||
LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest | Q37165210 | ||
Bmi1 lineage tracing identifies a self-renewing pancreatic acinar cell subpopulation capable of maintaining pancreatic organ homeostasis | Q37182612 | ||
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. | Q37352325 | ||
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis | Q37411831 | ||
Genetically engineered mouse models of pancreatic cancer: unravelling tumour biology and progressing translational oncology. | Q37923241 | ||
Dangerous liaisons: pancreatic stellate cells and pancreatic cancer cells | Q37982808 | ||
What we have learned about pancreatic cancer from mouse models. | Q37992454 | ||
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. | Q38329605 | ||
PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network | Q38626764 | ||
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer | Q39076225 | ||
STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. | Q39540918 | ||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | adenocarcinoma | Q356033 |
pancreatic adenocarcinoma | Q18556189 | ||
P304 | page(s) | 232-247 | |
P577 | publication date | 2013-02-11 | |
P1433 | published in | Molecular Oncology | Q2190736 |
P1476 | title | Genetically engineered mouse models of pancreatic adenocarcinoma | |
P478 | volume | 7 |
Q36546544 | Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3 |
Q96136047 | An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development |
Q36017810 | Animal Models of Gastrointestinal and Liver Diseases. The difficulty of animal modeling of pancreatic cancer for preclinical evaluation of therapeutics |
Q47201794 | Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts |
Q47690405 | CDKN2B deletion is essential for pancreatic cancer development instead of unmeaningful co-deletion due to juxtaposition to CDKN2A. |
Q39161835 | Cells of origin of pancreatic neoplasms |
Q91526219 | Characterization of genetic subclonal evolution in pancreatic cancer mouse models |
Q38165518 | Chromosome instability and carcinogenesis: insights from murine models of human pancreatic cancer associated with BRCA2 inactivation |
Q91595228 | Differential impact of the ERBB receptors EGFR and ERBB2 on the initiation of precursor lesions of pancreatic ductal adenocarcinoma |
Q91742604 | Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma |
Q92617609 | Drp1 Promotes KRas-Driven Metabolic Changes to Drive Pancreatic Tumor Growth |
Q39182842 | Drugging RAS: Know the enemy |
Q47111525 | Duct- and Acinar-Derived Pancreatic Ductal Adenocarcinomas Show Distinct Tumor Progression and Marker Expression. |
Q90139280 | Ductal vs. acinar? Recent insights into identifying cell lineage of pancreatic ductal adenocarcinoma |
Q41670877 | EMT and Treatment Resistance in Pancreatic Cancer. |
Q47424104 | ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1. |
Q38696102 | Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis |
Q38653925 | Establishment and characterization of a novel murine model of pancreatic cancer cachexia |
Q47101598 | Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer |
Q26781848 | GEMMs as preclinical models for testing pancreatic cancer therapies |
Q60959769 | GPER is a mechanoregulator of pancreatic stellate cells and the tumor microenvironment |
Q42109599 | Generation of a pancreatic cancer model using a Pdx1-Flp recombinase knock-in allele |
Q88688533 | Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets |
Q54118717 | Homozygous KSR1 deletion attenuates morbidity but does not prevent tumor development in a mouse model of RAS-driven pancreatic cancer. |
Q26828959 | Imaging and Therapy of Pancreatic Cancer with Phosphatidylserine-Targeted Nanovesicles |
Q40968374 | Independent and core pathways in oncogenic KRAS signaling |
Q91705514 | Inhibition of 15-PGDH causes Kras-driven tumor expansion through prostaglandin E2-ALDH1 signaling in the pancreas |
Q38878897 | Intravoxel incoherent motion analysis of abdominal organs: computation of reference parameters in a large cohort of C57Bl/6 mice and correlation to microvessel density |
Q53101926 | K-Ras(V14I) -induced Noonan syndrome predisposes to tumour development in mice. |
Q90207146 | KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer |
Q89918134 | Low Incidence of High-Grade Pancreatic Intraepithelial Neoplasia Lesions in a Crmp4 Gene-Deficient Mouse Model of Pancreatic Cancer |
Q47285433 | Malnutrition in Pancreatic Ductal Adenocarcinoma (PDA): Dietary Pancreatic Enzymes Improve Short-Term Health but Stimulate Tumor Growth |
Q41228738 | Matrix stiffness induces epithelial-mesenchymal transition and promotes chemoresistance in pancreatic cancer cells |
Q33624574 | Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward |
Q37119287 | Mounting Pressure in the Microenvironment: Fluids, Solids, and Cells in Pancreatic Ductal Adenocarcinoma |
Q47141518 | Multiplexed in vivo homology-directed repair and tumor barcoding enables parallel quantification of Kras variant oncogenicity. |
Q38707232 | Multiplexed pancreatic genome engineering and cancer induction by transfection-based CRISPR/Cas9 delivery in mice |
Q88963803 | Mutant Kras Dosage and Chromothripsis: The Right Ingredients for a Pancreatic Cancer Catastrophe |
Q28535288 | Novel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapy |
Q60949486 | Obesity-Linked Cancers: Current Knowledge, Challenges and Limitations in Mechanistic Studies and Rodent Models |
Q38684978 | Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma. |
Q36767415 | Pancreatic cancer stroma: friend or foe? |
Q101038680 | Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice |
Q48123886 | Role of metastasis-associated lung adenocarcinoma transcript-1 (MALAT-1) in pancreatic cancer. |
Q89475388 | Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer |
Q51097608 | Runx3 and Cell Fate Decisions in Pancreas Cancer. |
Q53229089 | SOX9 regulates ERBB signalling in pancreatic cancer development. |
Q37726658 | Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression. |
Q30641176 | Senescent cells communicate via intercellular protein transfer |
Q38264082 | Signal transduction: From the atomic age to the post-genomic era |
Q26783920 | Single and Multiple Gene Manipulations in Mouse Models of Human Cancer |
Q37583130 | Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression |
Q37706198 | Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models |
Q33827703 | The complex landscape of pancreatic cancer metabolism |
Q92932132 | The role of metabolic adaptation to nutrient stress in pancreatic cancer |
Q36724890 | Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment. |
Q49494945 | Understanding Disease Biology and Informing the Management of Pancreas Cancer With Preclinical Model Systems. |
Q47150678 | Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth |
Q28083091 | Utilizing past and present mouse systems to engineer more relevant pancreatic cancer models |
Q33943271 | Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer |
Search more.